Agenus Inc. Working Capital

Working Capital of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2020 was $-37.5 Million (a 52.69% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 45.61%
  • Annual Working Capital for 2019 was $-35.7 Million (a -628.8% decrease from previous year)
  • Annual Working Capital for 2018 was $6.75 Million (a -60.59% decrease from previous year)
  • Annual Working Capital for 2017 was $17.1 Million (a -66.08% decrease from previous year)
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Agenus Inc.

Most recent Working Capitalof AGEN including historical data for past 10 years.

Interactive Chart of Working Capital of Agenus Inc.

Agenus Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-37.51 $-24.57
2019 $-35.67 $-25.76 $17.2 $73.61 $-35.67
2018 $6.75 $9.45 $16.39 $35.03 $6.75
2017 $17.12 $29.94 $77.78 $101.6 $17.12
2016 $50.46 $74.68 $103.01 $130.35 $50.46
2015 $155.16 $180.66 $120.96 $64.16 $155.16
2014 $33.44 $39.61 $48.46 $60.89 $33.44
2013 $17.88 $21.22 $7.27 $12.57 $17.88
2012 $17.8 $20.96 $21.89 $20.44 $17.8
2011 $7.25 $10.12 $8.49 $11.33 $7.25
2010 $15.44 $-14.55 $25.45 $20.63 $15.44
2009 $26.18 $29.78 $26.18

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.